纳米微观层持续释放泌尿酶系统具有抗氧化特性,用于深静脉血栓塞治疗
Shun Xiao1, Xiaozhi Sun1, Chong Wang2
1Department of Vascular Surgery, Affiliated Hospital of Qingdao University, Qingdao University Qingdao Shandong China Qyfyliubing@163.com qduahvasc@163.com.
RSC advances
|February 29, 2024
概括
这项研究开发了一种用于深静脉血栓 (DVT) 的新型微球药物输送系统. 该系统有效地溶解血栓并防止新的血栓,为DVT提供了一个有前途的新疗法.
科学领域:
- 生物材料科学 生物材料科学
- 药理学 药理学是指药理学的学科.
- 血管生物学 血管生物学
背景情况:
- 深静脉血栓症 (DVT) 是一种严重的疾病,需要有效的治疗.
- 目前的静脉注射血栓抑制药物具有诸如短半衰期和狭窄的治疗指数等局限性.
- 需要先进的药物输送系统来改善DVT的管理.
研究的目的:
- 构建和评估一种用于治疗DVT的新型尿素酶载荷微球平台.
- 为了提高治疗效果和延长DVT的治疗时间.
- 开发一个多功能系统,解决血块溶解和预防新的血栓形成问题.
主要方法:
- 制造带有尿素酶载荷的甲基化物修饰的原形甲基化物基托桑微球.
- 利用静电相互作用进行尿素酶吸附和牛血清白蛋白进行稳定.
- 评估药物释放动力学,抗氧化活性,生物相容性,抗炎性质和血栓缓解疗效.
主要成果:
- 微球系统证明了有效的尿素酶吸附和稳定性.
- 实现了缓慢的药物释放动力学,促进了纤维素溶解.
- 该系统表现出显著的抗氧化活性,减少自由基,防止新的血栓形成.
- 实验结果证实了良好的生物相容性,抗炎作用和显著的血栓溶解活性.
结论:
- 开发的微球药物输送平台为DVT治疗提供了一种新的方法.
- 这种多功能系统有效地溶解了现有的血栓,并减轻了新的血块形成.
- 这项研究为通过先进的纳米技术来管理深静脉血栓形成提供了一个有希望的新方向.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
696
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
696
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
523
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
523


